TEL2 suppresses metastasis by down-regulating SERPINE1 in nasopharyngeal carcinoma

Oncotarget

Volumn 6, Issue 30, 2015, Pages 29240-29253

  Sang, Yi ^a,b   Chen, Ming yuan ^a   Luo, Donghua ^a   Zhang, Ru Hua ^a   Wang, Li ^a   Li, Mei ^a   Luo, Rongzhen ^a   Qian, Chao Nan ^a   Shao, Jian Yong ^a   Zeng, Yi Xin ^a   Kang, Tiebang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

Metastasis; Nasopharyngeal carcinoma; SERPINE1; TEL2

Indexed keywords

NERVE CELL ADHESION MOLECULE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TEL2; TUBULIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ETV7 PROTEIN, HUMAN; SERPINE1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CELL MIGRATION; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS INHIBITION; MICROARRAY ANALYSIS; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRESCHOOL CHILD; PROMOTER REGION; PROTEIN EXPRESSION; SCHOOL CHILD; ANIMAL; BINDING SITE; CARCINOMA; CELL MOTION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MORTALITY; NASOPHARYNGEAL NEOPLASMS; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; SECONDARY; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; BASE SEQUENCE; BINDING SITES; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHILD; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MICE, NUDE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NASOPHARYNGEAL NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-ETS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; YOUNG ADULT;

EID: 84945151455     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5074     Document Type: Article

References (39)

1. Ahmad A, Stefani S. Distant metastases of nasopharyngeal carcinoma: a study of 256 male patients. J Surg Oncol. 1986; 33:194-197.
2. Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, Feng QS, Low HQ, Zhang H, He F, Tai ES, Kang T, Liu ET, Liu J, Zeng YX. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010; 42:599-603.
3. Geara FB, Sanguineti G, Tucker SL, Garden AS, Ang KK, Morrison WH, Peters LJ. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol. 1997; 43:53-61.
4. Mak JP, Man WY, Chow JP, Ma HT, Poon RY. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells. Oncotarget. 2015.
5. Huang CJ, Leung SW, Lian SL, Wang CJ, Fang FM, Ho YH. Patterns of distant metastases in nasopharyngeal carcinoma. The Kaohsiung journal of medical sciences. 1996; 12:229-234.
6. Lee AW, Law SC, Foo W, Poon YF, Chan DK, O SK, Tung SY, Cheung FK, Thaw M, Ho JH. Nasopharyngeal carcinoma: local control by megavoltage irradiation. Br J Radiol. 1993; 66:528-536.
7. Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. Journal of the National Cancer Institute. 2011; 103:1761-1770.
8. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D, Qin L, Bao YN, Zheng FJ, Chia CS, Iyer NG, Kang TB, et al. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer research. 2011; 71:3162-3172.
9. Li XJ, Peng LX, Shao JY, Lu WH, Zhang JX, Chen S, Chen ZY, Xiang YQ, Bao YN, Zheng FJ, Zeng MS, Kang TB, Zeng YX, Teh BT, Qian CN. As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelialmesenchymal transition and activation of AKT signaling. Carcinogenesis. 2012; 33:1302-1309.
10. Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla SM, Villa S, Bolos V, Jorda M, Fabra A, Portillo F, Palacios J, Cano A. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer research. 2006; 66:9543-9556.
11. Tam WL, Weinberg RA. The epigenetics of epithelialmesenchymal plasticity in cancer. Nature medicine. 2013; 19:1438-1449.
12. Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukacisin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, Mercatali L, Amadori D, Haffty BG, Sinha S, Kang Y. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nature cell biology. 2012; 14:1212-1222.
13. Kar A, Gutierrez-Hartmann A. Molecular mechanisms of ETS transcription factor-mediated tumorigenesis. Crit Rev Biochem Mol Biol. 2013; 48:522-543.
14. Mukhopadhyay A, Khoury T, Stein L, Shrikant P, Sood AK. Prostate derived Ets transcription factor and Carcinoembryonic antigen related cell adhesion molecule 6 constitute a highly active oncogenic axis in breast cancer. Oncotarget. 2013; 4:610-621.
15. Vaughan CA, Deb SP, Deb S, Windle B. Preferred binding of gain-of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to multiple binding sites. Oncotarget. 2014; 5:417-427.
16. Cardone M, Kandilci A, Carella C, Nilsson JA, Brennan JA, Sirma S, Ozbek U, Boyd K, Cleveland JL, Grosveld GC. The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis. Molecular and cellular biology. 2005; 25:2395-2405.
17. Carella C, Potter M, Bonten J, Rehg JE, Neale G, Grosveld GC. The ETS factor TEL2 is a hematopoietic oncoprotein. Blood. 2006; 107:1124-1132.
18. Gu X, Shin BH, Akbarali Y, Weiss A, Boltax J, Oettgen P, Libermann TA. Tel-2 is a novel transcriptional repressor related to the Ets factor Tel/ETV-6. The Journal of biological chemistry. 2001; 276:9421-9436.
19. Potter MD, Buijs A, Kreider B, van Rompaey L, Grosveld GC. Identification and characterization of a new human ETS-family transcription factor, TEL2, that is expressed in hematopoietic tissues and can associate with TEL1/ETV6. Blood. 2000; 95:3341-3348.
20. Koensgen D, Mustea A, Denkert C, Sun PM, Lichtenegger W, Sehouli J. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. Anticancer research. 2006; 26:1683-1689.
21. Nishioka N, Matsuoka T, Yashiro M, Hirakawa K, Olden K, Roberts JD. Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo. Cancer science. 2012; 103:228-232.
22. Czekay RP, Wilkins-Port CE, Higgins SP, Freytag J, Overstreet JM, Klein RM, Higgins CE, Samarakoon R, Higgins PJ. PAI-1: An Integrator of Cell Signaling and Migration. International journal of cell biology. 2011; 2011:562481.
23. Bashar H, Urano T, Fukuta K, Pietraszek MH, Hata M, Suzuki K, Kawabe K, Takada Y, Takada A. Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. Urologia internationalis. 1994; 52:4-8.
24. Bhoumik A, Ronai Z. ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell cycle. 2008; 7:2341-2345.
25. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007; 21:868-876.
26. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer research. 2000; 60:636-643.
27. Maeda Y, Souma M, Kasakura S. [Plasma PAI-1 levels in patients with various tumors with or without metastasis]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 1991; 32:927-930.
28. Wu CC, Chien KY, Tsang NM, Chang KP, Hao SP, Tsao CH, Chang YS, Yu JS. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics. 2005; 5:3173-3182.
29. Kim JI, Jung KJ, Jang HS, Park KM. Gender-specific role of HDAC11 in kidney ischemia-and reperfusioninduced PAI-1 expression and injury. American journal of physiology Renal physiology. 2013; 305:F61-70.
30. Wan YZ, Gao P, Zhou S, Zhang ZQ, Hao DL, Lian LS, Li YJ, Chen HZ, Liu DP. SIRT1-mediated epigenetic downregulation of plasminogen activator inhibitor-1 prevents vascular endothelial replicative senescence. Aging cell. 2014; 13:890-899.
31. Kasza A. Signal-dependent Elk-1 target genes involved in transcript processing and cell migration. Biochimica et biophysica acta. 2013; 1829:1026-1033.
32. Nakatsuka H, Sokabe T, Yamamoto K, Sato Y, Hatakeyama K, Kamiya A, Ando J. Shear stress induces hepatocyte PAI-1 gene expression through cooperative Sp1/Ets-1 activation of transcription. American journal of physiology Gastrointestinal and liver physiology. 2006; 291:G26-34.
33. Tanaka S, Nakao K, Sekimoto T, Oka M, Yoneda Y. Cell density-dependent nuclear accumulation of ELK3 is involved in suppression of PAI-1 expression. Cell structure and function. 2013; 38:145-154.
34. Xu S, Feng Z, Zhang M, Wu Y, Sang Y, Xu H, Lv X, Hu K, Cao J, Zhang R, Chen L, Liu M, Yun JP, Zeng YX, Kang T. hSSB1 binds and protects p21 from ubiquitinmediated degradation and positively correlates with p21 in human hepatocellular carcinomas. Oncogene. 2011; 30:2219-2229.
35. Xu S, Wu Y, Chen Q, Cao J, Hu K, Tang J, Sang Y, Lai F, Wang L, Zhang R, Li SP, Zeng YX, Yin Y, Kang T. hSSB1 regulates both the stability and the transcriptional activity of p53. Cell research. 2013; 23:423-435.
36. Sanjana NE, Cong L, Zhou Y, Cunniff MM, Feng G, Zhang F. A transcription activator-like effector toolbox for genome engineering. Nature protocols. 2012; 7:171-192.
37. Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, Lin Y, Yao J, Shi J, Kang T, Lorkiewicz P, St Clair D, Hung MC, Evers BM, Zhou BP. Loss of FBP1 by Snailmediated repression provides metabolic advantages in basal-like breast cancer. Cancer cell. 2013; 23:316-331.
38. Lv XB, Xie F, Hu K, Wu Y, Cao LL, Han X, Sang Y, Zeng YX, Kang T. Damaged DNA-binding protein 1 (DDB1) interacts with Cdh1 and modulates the function of APC/CCdh1. The Journal of biological chemistry. 2010; 285:18234-18240.
39. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Der Pathologe. 1987; 8:138-140.